Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
extension symbols : Capr save search
Capricor Therapeutics Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
Published: 2023-06-30 (Crawled : 13:00) - globenewswire.com
CAPR | $5.07 0.4% 170K
|
Health Technology
|
| O: 1.46%
H: 0.23%
C: -1.85%
cap-1002 label positive ongoing extension therapeutics duchenne results study
Capricor Therapeutics to Present 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
Published: 2023-06-13 (Crawled : 13:20) - globenewswire.com
CAPR | $5.07 0.4% 170K
|
Health Technology
|
| O: 0.65%
H: 4.7%
C: 1.92%
cap-1002 label ongoing extension therapeutics duchenne results study
Capricor Therapeutics Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients
Published: 2023-01-25 (Crawled : 13:00) - globenewswire.com
CAPR | $5.07 0.4% 170K
|
Health Technology
|
| O: -5.26%
H: 7.64%
C: 1.39%
cap-1002 ongoing label extension therapeutics duchenne positive results study
Capricor Therapeutics to Present One-Year Results from HOPE-2 Open Label Extension Study at World Muscle Society 2022
Published: 2022-10-06 (Crawled : 13:20) - globenewswire.com
CAPR | $5.07 0.4% 170K
|
Health Technology
|
| O: -0.66%
H: 1.73%
C: -2.31%
label extension therapeutics results study
Capricor Therapeutics Announces Statistically Significant Clinical Benefits in Skeletal Muscle Function in Non-Ambulant Duchenne Muscular Dystrophy Patients Treated with CAP-1002 in HOPE-2 Open Label Extension Study
Published: 2022-06-27 (Crawled : 12:20) - biospace.com/
CAPR | $5.07 0.4% 170K
|
Health Technology
|
| O: 2.0%
H: 3.26%
C: -4.13%
cap-1002 label extension therapeutics duchenne benefits
Capricor Therapeutics to Present One-Year Efficacy Results from its Ongoing HOPE-2 Open Label Extension Study at 2022 Parent Project Muscular Dystrophy Annual Conference
Published: 2022-06-17 (Crawled : 13:20) - globenewswire.com
CAPR | $5.07 0.4% 170K
|
Health Technology
|
| O: 2.53%
H: 11.11%
C: 5.43%
ongoing conference label extension therapeutics results
Capricor Therapeutics to Present Findings from HOPE-2 Open-Label Extension Study at Parent Project Muscular Dystrophy (PPMD) 2021 Virtual Annual Conference
Published: 2021-06-17 (Crawled : 13:15) - globenewswire.com
CAPR | $5.07 0.4% 170K
|
Health Technology
|
| O: 0.45%
H: 22.17%
C: 14.48%
conference
Gainers vs Losers
| 71% | 29% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.0503 39.72% 320M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
NVFY | $2.65 25.59% 33M
|
Consumer Durables
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.